Patient-Centric Drug Delivery Strategies For Oral Paediatric Products



22nd April 2015 | 3AM ET / 8AM GMT / 9AM CET / 5PM SGT | Dr. Carsten Timpe Senior Principal Scientist at Hoffman La Roche AG and Dr. Paolo Gatti Research Fellow and Formulation Manager for Aptalis Pharmaceutical Technologies |WATCH FOR FREE

carstenDr Carsten Timpe is currently a Senior Principal Scientist at Hoffman La Roche AG in Basel Switzerland, focusing on early drug development. Previously he held positions at Novartis, Lilly and Schering/Jenapharm.
Dr Timpe has 20 years of experience in solid dosage form development from early to late stage and is the inventor/co-inventor of multiple international formulation patents.
Dr Timpe completed his Ph.D thesis in Pharmaceutical Chemistry at the Phillips University Marburg, Germany.
 
PaoloGattiPhDDr. Paolo Gatti, PhD, is Research Fellow and Formulation Manager for Aptalis Pharmaceutical Technologies R&D Team. His responsibilities include oversight of drug product development, bioavailability enhancement, controlled release and taste technologies formulation scientists and technicians. He also conducts scouting and due diligence review and evaluation for new technologies.
He graduated with honours in Pharmaceutical Chemistry and defended his PhD thesis in Pharmaceutical Sciences at the University of Genova in 1999.
Dr. Gatti began his pharmaceutical career in 1999 joining the Oral Solid Department of Pharmacia & Upjohn R&D as a junior formulation scientist. Over the successive eight years, following  merger, acquisition and spin-off involving the company, he held positions of increasing responsibility at Pharmacia, Pfizer and Nerviano Medical Sciences becoming senior scientist in charge of the Solid Dosage Forms Development Laboratory.
He is teacher of the Formulation Development Post Degree Master at the University of Pavia and is regularly invited as lecturer in universities and professional advancement courses. He is also a published author.
 
Sponsored by Aptalis Pharmaceutical Technologies
 
Aptalis_Pharmaceutical_Technologies_Logo_New
 
Aptalis Pharmaceutical Technologies, an Actavis company, is focused on developing high-value products with robust, defensible proprietary positions that grow the commercial value of our partners’ portfolios.
We have a variety of products available for licensing across multiple therapeutic categories and collaborate with our partners to develop customized, value-added Rx and OTC products.
We develop and manufacture enhanced pharmaceutical products based on our broad range of proprietary oral drug delivery platforms, including:
1) Taste masking and ODTs
2) Customized drug release
3) Bioavailability enhancement
We utilize these technologies to develop novel prescription and OTC products that have advantages over existing products and address unmet medical needs.
Our integrated R&D and manufacturing teams in the U.S. and Europe work with our partners from formulation through scale-up and commercial-scale manufacturing.
Since 2009, our partners have commercialized more than 40 products worldwide.
To learn more speak with one of our licensing representatives, or visit: www.AptalisPharmaceuticalTechnologies.com.
 
 


We will not sell your information to a third party. See our Privacy Policy

Biopharma Webinars